"Vitamin B3"@en . . . . . . . . . . . . . . . . . . . . . . . "# Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V: Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J. 2005 May 15;388(Pt 1):309-16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15651982"@en . . . . . . . . . . . . . . . . . . . . . . . "Avoid alcohol."@en . "Nikotinsaeure"@en . . . . . . . . . . . . . "Nicotinic Acid"@en . . . . . . . . . . . "beta-Pyridinecarboxylic acid"@en . . . . . . . . "A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has pellagra-curative, vasodilating, and antilipemic properties. [PubChem]"@en . . . "Acidum Nicotinicum"@en . . . "PP Factor"@en . "3-Pyridylcarboxylic acid"@en . "Nicotinic acid can cause vasodilation of cutaneous blood vessels resulting in increased blood flow, principally in the face, neck and chest. This produces the niacin- or nicotinic acid-flush. The niacin-flush is thought to be mediated via the prostaglandin prostacyclin. Histamine may also play a role in the niacin-flush. Flushing is the adverse reaction first observed after intake of a large dose of nicotinic acid, and the most bothersome one. LD₅₀ 7000 mg/kg (Rat)"@en . . "Both nicotinic acid and nicotinamide are efficiently absorbed from the stomach and small intestine."@en . "Acido nicotinico"@en . . "Pellagra preventive factor"@en . "20-45 minutes."@en . . "Niacin"@en . . . . . . "Niacin"@en . . . . . . . . . "pyridine-\u03B2-carboxylic acid"@en . . . "Pyridine-beta-carboxylic acid"@en . . . "investigational"@en . . . . . . " "@en . . . . . "Anti-pellagra vitamin"@en . . . "3-carboxypyridine"@en . . . "For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy."@en . . "\u03B2-pyridinecarboxylic acid"@en . "Acide Nicotinique"@en . . . . . . "nutraceutical"@en . . . . . . . . "Take with food."@en . . . . . . . "3-Pyridinecarboxylic acid"@en . "Niacin binds to Nicotinate D-ribonucleotide phyrophsopate phosphoribosyltransferase, Nicotinic acid phosphoribosyltransferase, Nicotinate N-methyltransferase and the Niacin receptor. Niacin is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital cofactors for dozens of enzymes. The mechanism by which niacin exerts its lipid lowering effects is not entirely understood, but may involve several actions, including a decrease in esterification of hepatic triglycerides. Niacin treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions."@en . . . . . . . . . "P.P. factor"@en . . "Humans and other mammals"@en . . "Joseph E. Toomey, Jr., \"Electrochemical synthesis of niacin and other N-heterocyclic compounds.\" U.S. Patent US5002641, issued 1914."@en . . "approved"@en . "M-Pyridinecarboxylic Acid"@en . . . . "59-67-6"@en . . . . . . . . . . . . . . .